322
On 25 May 2022 the Supreme Court overturned the Court of Appeal’s ruling on costs in Pfizer and Flynn Pharma and concluded that the Competition Appeal Tribunal (CAT) had applied the correct test when awarding a proportion of their costs against the CMA. The Court of Appeal had held that, (...)